PROTAC Compounds for CDK2 and CDK9 Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current inhibitors and treatments for CDK2 and CDK9 are limited in effectiveness and specificity, particularly in addressing cancer and HIV infection, and there is a need for compounds that can selectively degrade these proteins to inhibit their activity.
Innovation Solution
Development of compounds that utilize PROTAC technology to bind to CDK2 and/or CDK9, linking an inhibitor to an E3 ubiquitin ligase through a linker, facilitating the degradation of these proteins via the proteasome pathway.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional CDK2 and CDK9 inhibitors are used, then some therapeutic effect is achieved, but selectivity and efficacy are limited
Solution Approach 1:
The PROTAC compound is segmented into three functional modules: a CDK2/CDK9 binder moiety, an E3 ligase ligand moiety, and a linker connecting them. This segmentation allows each module to independently perform its function - the binder targets the specific kinase, the E3 ligase ligand recruits the degradation machinery, and the linker bridges them - thereby achieving high selectivity for CDK2/CDK9 while maintaining therapeutic efficacy through selective degradation.
2Reliability
If PROTAC technology is used to selectively degrade CDK2 and CDK9, then selectivity and efficacy are improved, but the structural complexity of the compound increases
Solution Approach 1:
The invention merges three separate functional components (CDK2/CDK9 binder, E3 ligase ligand, and linker) into a single unified PROTAC molecule. This merging allows the compound to simultaneously perform target recognition, recruitment of degradation machinery, and catalysis of protein degradation, achieving high selectivity and efficacy while managing structural complexity through rational molecular design.
3Reliability
If current treatments for cancer and HIV are used, then some therapeutic benefit is achieved, but safety and stability are insufficient
Solution Approach 1:
The PROTAC compound employs a self-service mechanism where the recruited E3 ligase and cellular proteasome systems automatically perform the degradation of CDK2/CDK9 without requiring additional external enzymes or complex delivery systems. This leverages the cell's own degradation machinery to achieve stable and safe therapeutic effects, reducing the need for additional stabilizing components.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds demonstrate high selectivity and efficacy in inhibiting or degrading CDK2 and/or CDK9, offering potential therapeutic benefits for cancer and HIV infection with improved safety and stability.
Implementation Method 1
linking an inhibitor to an E3 ubiquitin ligase through a linker, facilitating the degradation of these proteins via the proteasome pathway
Data Source
Figure 1~2
Figure 3
Figure 3
AI summary
The present invention provides a compound of a certain chemical structure or a pharmaceutically acceptable salt thereof, exhibiting activity of inhibiting or degrading CDK2 and/or CDK9, and a method for preparing thereof. The present invention provides a composition comprising the compound or a pharmaceutically acceptable salt thereof. The present invention provides use of the compound, a salt thereof, or a composition comprising the same in inhibiting or degrading CDK2 and/or CDK9 and medicinal use of the same in preventing or treating a disease associated therewith. The present invention further provides method for preventing or treating a disease associated with CDK2 and/or CDK9, comprising administering the compound, a salt thereof, or a composition comprising the same to a subject in need of treatment.